J&J Could Have Warned About Risperdal, Plaintiff Tells SCOTUS

A $70 million Risperdal award against Johnson & Johnson and unit Janssen Pharmaceuticals Inc. was properly upheld by a Pennsylvania court, because FDA regulations didn’t prevent manufacturers from warning about the risk of it causing breast growth in males, a man who alleges childhood use caused him to develop female-like breasts told the U.S. Supreme Court.

Risperdal, an antipsychotic drug, hadn’t been approved for children when A.Y. was first prescribed the drug in 2003; it was an “off-label” use. A.Y. says Janssen didn’t warn that Risperdal could cause breast growth in males, and says a warning would have prevented his ...